Researchers identified over a thousand genetic markers for Type 2 diabetes, marking a significant step toward personalized diabetes management.
In the largest genome-wide association study to date on Type 2 diabetes, a team of international researchers, co-led by a University of Massachusetts Amherst genetic epidemiologist, has located 1,289 genetic markers associated with Type 2 diabetes (145 of which are newly identified) and generated risk scores for diabetes complications.
In research published today (February 19) in the journal Nature that advances understanding of the inheritability of Type 2 diabetes, the scientists used cutting-edge computational approaches to identify eight distinct mechanistic clusters of genetic variants linked to the disease. They also discovered associations between individual clusters and diabetes complications.
“We tried to figure out some of the mechanisms for how these genetic variants are working – and we did,” says co-senior author Cassandra Spracklen, assistant professor of biostatistics and epidemiology in the School of Public Health and Health Sciences.
Ultimately, the goal is to identify potential genetic targets to treat or even cure the chronic metabolic disease that affects and sometimes debilitates more than 400 million adults worldwide, according to the International Diabetes Federation.
Innovations in Diabetes Research
The study – emerging from the newly formed Type 2 Diabetes Global Genomics Initiative – included data from a highly diverse group of more than 2.5 million individuals, 428,452 of whom have Type 2 diabetes.
“We found eight clusters of Type 2 diabetes-associated variants that have also been associated with other diabetes risk factors – such as obesity and liver-lipid metabolism – suggesting the mechanisms for how the variants may be acting to cause diabetes,” Spracklen says. “Then we asked if these clusters were also associated with Type 2 diabetes complications? And we found that several of them to also associated with vascular complications, such as coronary artery disease and end-stage diabetic nephropathy.”
Towards Personalized Diabetes Management
Even though effective treatments are available for Type 2 diabetes, the option for precision medicine tailored to the individual is still limited. For many people with the disease, treatment strategies still rely on trial and error. Being better able to understand the disease mechanisms will help predict individuals’ risk of Type 2 diabetes and allow for earlier intervention.
“We’re trying to understand how diabetes develops,” says Spracklen, adding that the new research includes data from cohorts not available in an earlier genome-wide association study published in 2022 in Nature Genetics, for which Spracklen was co-first author. “And we’re trying to better understand how these genetic variants are actually working within a biological tissue or at the cellular level, which can ultimately lead to new drug targets and treatments.”
Senior corresponding author Eleftheria Zeggini, director of the Institute of Translational Genomics at Helmholtz Munich and a professor at the Technical University of Munich, notes that collaboration among scientists is essential for evaluating vast patient data and achieving a comprehensive understanding of genomic risk variants.
“The genetic information in our cells harbors secrets about the risks, progression, and complications of many diseases,” she says. “Our work leads to an improved understanding of disease-causing biological mechanisms. Better knowledge of progression risk for Type 2 diabetes complications can help put in place early interventions to delay or even prevent these debilitating medical conditions.”
The paper concludes, “Our findings … may offer a route to optimize global access to genetically informed diabetes care.”
Reference: “Genetic drivers of heterogeneity in type 2 diabetes pathophysiology” by Ken Suzuki, Konstantinos Hatzikotoulas, Lorraine Southam, Henry J. Taylor, Xianyong Yin, Kim M. Lorenz, Ravi Mandla, Alicia Huerta-Chagoya, Giorgio E. M. Melloni, Stavroula Kanoni, Nigel W. Rayner, Ozvan Bocher, Ana Luiza Arruda, Kyuto Sonehara, Shinichi Namba, Simon S. K. Lee, Michael H. Preuss, Lauren E. Petty, Philip Schroeder, Brett Vanderwerff, Mart Kals, Fiona Bragg, Kuang Lin, Xiuqing Guo, Weihua Zhang, Jie Yao, Young Jin Kim, Mariaelisa Graff, Fumihiko Takeuchi, Jana Nano, Amel Lamri, Masahiro Nakatochi, Sanghoon Moon, Robert A. Scott, James P. Cook, Jung-Jin Lee, Ian Pan, Daniel Taliun, Esteban J. Parra, Jin-Fang Chai, Lawrence F. Bielak, Yasuharu Tabara, Yang Hai, Gudmar Thorleifsson, Niels Grarup, Tamar Sofer, Matthias Wuttke, Chloé Sarnowski, Christian Gieger, Darryl Nousome, Stella Trompet, Soo-Heon Kwak, Jirong Long, Meng Sun, Lin Tong, Wei-Min Chen, Suraj S. Nongmaithem, Raymond Noordam, Victor J. Y. Lim, Claudia H. T. Tam, Yoonjung Yoonie Joo, Chien-Hsiun Chen, Laura M. Raffield, Bram Peter Prins, Aude Nicolas, Lisa R. Yanek, Guanjie Chen, Jennifer A. Brody, Edmond Kabagambe, Ping An, Anny H. Xiang, Hyeok Sun Choi, Brian E. Cade, Jingyi Tan, K. Alaine Broadaway, Alice Williamson, Zoha Kamali, Jinrui Cui, Manonanthini Thangam, Linda S. Adair, Adebowale Adeyemo, Carlos A. Aguilar-Salinas, Tarunveer S. Ahluwalia, Sonia S. Anand, Alain Bertoni, Jette Bork-Jensen, Ivan Brandslund, Thomas A. Buchanan, Charles F. Burant, Adam S. Butterworth, Mickaël Canouil, Juliana C. N. Chan, Li-Ching Chang, Miao-Li Chee, Ji Chen, Shyh-Huei Chen, Yuan-Tsong Chen, Zhengming Chen, Lee-Ming Chuang, Mary Cushman, John Danesh, Swapan K. Das, H. Janaka de Silva, George Dedoussis, Latchezar Dimitrov, Ayo P. Doumatey, Shufa Du, Qing Duan, Kai-Uwe Eckardt, Leslie S. Emery, Daniel S. Evans, Michele K. Evans, Krista Fischer, James S. Floyd, Ian Ford, Oscar H. Franco, Timothy M. Frayling, Barry I. Freedman, Pauline Genter, Hertzel C. Gerstein, … , Takashi Kadowaki, John C. Chambers, Maggie C. Y. Ng, Xueling Sim, Jennifer E. Below, Philip S. Tsao, Kyong-Mi Chang, Mark I. McCarthy, James B. Meigs, Anubha Mahajan, Cassandra N. Spracklen, Josep M. Mercader, Michael Boehnke, Jerome I. Rotter, Marijana Vujkovic, Benjamin F. Voight, Andrew P. Morris and Eleftheria Zeggini, 19 February 2024, Nature.
DOI: 10.1038/s41586-024-07019-6
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
1 Comment
Eventually, instead of hundreds of tests for metabolic disorders, every child will have a full DNA sequence done that will detect, not just things like PKU, but also diabetes and heart disease risk factors. They will be told what to watch for, and some will know which foods they should avoid and/or be treated for certain diseases before they become active! Of course, some will choose to ignore medical advice. Then the question will become “does society have a responsibility to provide medical treatment when the patient refuses a treatment known to be effective and wants treatment known not to be effective “?.